1. A method of treating rheumatoid arthritis (RA) in a patient, comprising: a) administering to the patient an IL-17 antibody in three doses of approximately 10 mg / kg； and b) then administering to the patient an IL-17 antibody in doses of from about 75 to about 150 mg each month, wherein the IL-17 antibody binds to an epitope of an IL-17 homodimer having two chains of the mature IL-17 protein, wherein said epitope contains Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 in one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 in another chain； wherein the IL-17 antibody has a K of approximately 100-200 pM and the IL-17 antibody has an in vivo half-life of approximately 4 weeks. The method of claim 1, wherein the patient is a patient with high risk RA. The method of claim 1, wherein, prior to step a), the patient is selected for treatment based on the fact that the patient is a patient with high-risk RA. The method of claim 1, wherein the first dose of about 10 mg / kg according to step a) is delivered during week zero, the second dose of about 10 mg / kg is delivered during week two, and the third dose of about 10 mg / kg is delivered during week four. .5. The method of claim 1, wherein the first monthly dose according to step b) is delivered during the eighth week. The method according to claim 3, in which the patient with high-risk RA: a) is seropositive for rheumatoid factor (RF +), antibodies against citrulline protein (ACPA +), or both RF + and ACPA +； and b) has a high level of C-reactive protein (CRP), a high erythrocyte sedimentation rate (ESR), or both a high level of CRP and a high ESR. 7. The method according to claim 6, in which a high level of CRP is ≥10 mg / L as measured using hsCRP. The method according to claim 6, in which a high ESR≥281. Способ лечения ревматоидного артрита (РА) у пациента, включающий:a) введение пациенту IL-17-антитела в виде трех доз приблизительно по 10 мг/кг； иb) затем введение пациенту IL-17-антит
